Literature DB >> 10638704

IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis.

A C Hobeika1, W Etienne, B A Torres, H M Johnson, P S Subramaniam.   

Abstract

Interferons (IFN) inhibit the growth of tumor cells by blocking the progression of their cell cycle. Recently, we showed that this cell cycle inhibition correlates with the ability of IFN to upregulate the cyclin-dependent kinase inhibitor p21(WAF1). This, however, is not proof of a causal relationship. Using p21(WAF1)-deficient cells derived from the HCT116 colon adenocarcinoma cell line, we now show that p21(WAF1) is indeed responsible for the antiproliferative effects of the type II IFN, IFN-gamma. IFN-gamma upregulated p21(WAF1) expression in a p53-independent manner, decreased cyclin-dependent kinase 2 activity, and inhibited entry into the S phase of the cell cycle in p21+/+ but not in p21-/- HCT116 cells. We additionally found that the lack of p21(WAF1) expression resulted in an increase in the ability of IFN-gamma to induce apoptosis, as reflected by an earlier induction of DNA fragmentation and caspase 3 activity in p21-/- cell. Our results indicate that p21(WAF1) expression is necessary for IFN-gamma-mediated cell cycle inhibition and suppression of IFN-gamma-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10638704     DOI: 10.1089/107999099312812

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  22 in total

1.  Regulation of apoptosis by type III interferons.

Authors:  W Li; A Lewis-Antes; J Huang; M Balan; S V Kotenko
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

2.  USP18 (UBP43) Abrogates p21-Mediated Inhibition of HIV-1.

Authors:  Edmund Osei Kuffour; Kerstin Schott; Ananda Ayyappan Jaguva Vasudevan; Jessica Holler; Wolfgang A Schulz; Philipp A Lang; Karl S Lang; Baek Kim; Dieter Häussinger; Renate König; Carsten Münk
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 3.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

4.  Interferon-gamma enhances radiation-induced cell death via downregulation of Chk1.

Authors:  Kwang Seok Kim; Kyu Jin Choi; Sangwoo Bae
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

5.  Genomic regulation of senescence and innate immunity signaling in the retinal pigment epithelium.

Authors:  Edward Chaum; Christina S Winborn; Sujoy Bhattacharya
Journal:  Mamm Genome       Date:  2015-05-12       Impact factor: 2.957

6.  Rb-E2F-HDAC Repressor Complexes Control Interferon-Induced Repression of Adenovirus To Promote Persistent Infection.

Authors:  Sydney Snaider; Yueting Zheng; Patrick Hearing
Journal:  J Virol       Date:  2022-05-12       Impact factor: 6.549

7.  Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity.

Authors:  Brian R Lawson; Roberto Baccala; Jianxun Song; Michael Croft; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  J Exp Med       Date:  2004-02-16       Impact factor: 14.307

8.  Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.

Authors:  Mark J Dobrzanski
Journal:  Front Oncol       Date:  2013-03-26       Impact factor: 6.244

9.  Novel molecular, cytotoxical, and immunological study on promising and selective anticancer activity of mung bean sprouts.

Authors:  Rand R Hafidh; Ahmed S Abdulamir; Fatimah Abu Bakar; Farid Azizi Jalilian; Faridah Abas; Zamberi Sekawi
Journal:  BMC Complement Altern Med       Date:  2012-11-05       Impact factor: 3.659

10.  rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition.

Authors:  Bohuslav Melichar; Wei Hu; Rebecca Patenia; Karolina Melicharová; Stacie T Gallardo; Ralph Freedman
Journal:  J Transl Med       Date:  2003-09-19       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.